Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of “Moderate Buy” by Analysts
Shares of Immuneering Corporation (NASDAQ:IMRX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the five analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month target […]
Shares of Immuneering Corporation (NASDAQ:IMRX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the five analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month target […]
